Results 61 to 70 of about 30,729 (226)
Addiction, EarlyView.Abstract Background and aims Tobacco‐free nicotine pouches (NPs) are oral nicotine products promoted by manufacturers and some researchers as tools that may reduce nicotine cravings and support smoking reduction or cessation. However, evidence regarding their actual clinical impact remains limited.
Javad Heshmati +6 more
wiley +1 more source
Delayed allergic reaction from bupropion in a 27-year-old male with MDD: A case report and literature review [PDF]
Mental Health ClinicianIntroduction Bupropion is an antidepressant approved for the treatment of major depressive disorder (MDD), seasonal affective disorder, and smoking cessation. Nausea, headache, tremor, and insomnia are well-known adverse effects of this medication.
Ana Anghel, BSc(Psych) +1 more
doaj +1 more source
Varenicline for cannabis use disorder: A randomized controlled trial
Addiction, EarlyView.Abstract Background and aims Although cannabis use is widespread and prevalence of cannabis use disorder (CUD) is increasing, limited advancements have been made in CUD medication development. The objective of this study was to test the efficacy of varenicline with medical management for reducing cannabis use in treatment‐seeking individuals with CUD ...
Aimee L. McRae‐Clark +8 more
wiley +1 more source
Frontiers in PsychiatryAlcohol Use Disorder (AUD) is a prevalent condition often co-occurring with affective disorders. Bupropion, a medication used to treat affective disorders, acts by inhibiting dopamine (DA) and norepinephrine (NE) reuptake, potentially helping to ...
Xiangqi Kong +5 more
doaj +1 more source
Rapid bupropion-induced hepatotoxicity: a case report and review of the literature
Journal of Medical Case Reports, 2018 Background Bupropion is an antidepressant that is also used as a non-nicotine method to aid in smoking cessation. Bupropion-induced hepatotoxicity is quoted to affect between 0.1% and 1% of treated patients with either a hepatocellular and/or cholestatic
Sulakchanan Anandabaskaran, Vincent Ho
doaj +1 more source
Addiction, EarlyView.Abstract Aim Our primary aim was to conduct a network meta‐analysis (NMA) for the effectiveness, safety and acceptability of all psychosocial interventions and all pharmacotherapies for cannabis use disorder (CUD). Methods We conducted a NMA of studies identified from two completed systematic reviews examining the effectiveness, safety and ...
Monika Halicka +6 more
wiley +1 more source
Trials, 2019 BackgroundThe purpose of this study was to compare the effect of 300 mg of bupropion and 8 mg of buprenorphine per day on the treatment of methamphetamine withdrawal cravings over a 2-week treatment interval.MethodSixty-five methamphetamine-dependent men
J. Ahmadi, A. Sahraian, Mehdi Biuseh
semanticscholar +1 more source
Beyond abstinence: Redefining success in cannabis use disorder treatment
Addiction, EarlyView.Abstract Background Over two decades of pharmacotherapy research has yet to yield a consistently effective medication for cannabis use disorder (CUD), in part because clinical trials have frequently prioritized abstinence as a primary or key endpoint.
Tobias B. Atkin +3 more
wiley +1 more source
Charcoal hemoperfusion in bupropion overdose
Journal of the Formosan Medical Association, 2014 Bupropion is a relatively new and popular medication for depression, with seizures as its major side effect. In the literature, there are insufficient data about hemodialysis following bupropion overdose.
Hızır Ufuk Akdemir +5 more
doaj +1 more source
The American Journal on Addictions, EarlyView.Abstract Background and Objectives Managing substance use disorders (SUDs) is limited by the lack of longitudinal clinical data during active use and recovery. Wearable devices may help address this gap by capturing physiological and behavioral data in real‐world settings.
Alexandra Sas +10 more
wiley +1 more source